Icarus Consultants

What’s hot at ASCO 2012?

Daedalus — Tue, 15 May 2012 21:14:58 +0000

The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) takes place in Chicago in just over two weeks time from June 1 – 5. The ASCO abstracts will be publicly available tomorrow (May 16) at 6pm EDT. … Continue reading →

AACR 2012 meeting: a window into potential new cancer drugs

Daedalus — Sat, 21 Apr 2012 14:07:50 +0000

Bill Sellers gives an AACR plenary talk The annual meeting of the American Association for Cancer Research (AACR), held in Chicago earlier this month, is one of the most important meetings of the year for cancer scientists, pharma/biotech drug development … Continue reading →

Do you know who your thought leaders are and what they think about your product?

Daedalus — Sat, 10 Mar 2012 15:31:08 +0000

One of the emerging trends we saw at the recent European Association of Urology (EAU) Congress in Paris was an increase in the number of plenary and session presentations by physicians from Eastern European countries. This trend is set to … Continue reading →

Abiraterone price may be discounted 40% for UK NICE approval

Daedalus — Sat, 03 Mar 2012 12:34:01 +0000

At the recent European Association of Urology (EAU) Annual Congress in Paris, one of the rumours was that the price of abiraterone (Zytiga) has been discounted 40% to the UK National Health Service (NHS) in order to obtain reimbursement approval … Continue reading →

Are you adapting to the changing prostate cancer market?

Daedalus — Fri, 10 Feb 2012 15:18:10 +0000

The prostate cancer market continues to evolve at a fast pace. Companies with products on the market or in development will need to adapt their marketing strategy to the changing prostate cancer market dynamics. Some of the recent news includes: … Continue reading →

Understanding the biology of colorectal cancer will lead to more rational drug development

Daedalus — Tue, 31 Jan 2012 13:42:29 +0000

Cancer drug development is becoming more targeted and focused as a result of scientific advances. The understanding of ALK gene rearrangements in lung cancer led to the development of crizotinib (Xalkori) for the subset of patients who are ALK-positive. Sally … Continue reading →

Pharma Conference Coverage Strategy

Daedalus — Mon, 23 Jan 2012 12:43:42 +0000

We live in a world of data that threatens to overwhelm our work and personal lives. Part of the reason for this is the price of data storage continues to fall dramatically. Today, an external hard drive offers a 1TB … Continue reading →

Follow JP Morgan Healthcare Conference #JPM12

Daedalus — Sun, 08 Jan 2012 18:22:42 +0000

This weeks sees the start of the JP Morgan Healthcare Conference in San Francisco. Thousands of pharma/biotech investors, analysts, venture capitalists and company executives will meet to pitch, showcase their companies and make deals. A lot of people seemed to … Continue reading →

Bruton’s Tyrosine Kinase is a novel target for B-Cell Malignancies

Daedalus — Thu, 05 Jan 2012 13:24:11 +0000

ASH 2011 Poster Session Two Bruton’s Tyrosine Kinase (BTK) inhibitors in clinical development (PCI-32765 & AVL-292) generated a lot of interest at the recent American Society of Hematology (ASH) annual meeting in San Diego. Sally Church on Pharma Strategy Blog … Continue reading →

What will be hot at ASCO 2012 in Chicago?

Daedalus — Wed, 04 Jan 2012 12:54:32 +0000

ASCO 2012 is in Chicago from June 1 – 5 While everyone is busy making predictions about what the New Year will bring, we are already thinking about what are going to be hot topics at the 2012 annual meeting … Continue reading →